A Phase 2 interventional study of Radiotherapy dose fractionation regimen in Non-Small Cell Carcinoma of Lung, sponsored by Quanzhou First Hospital. Not yet recruiting at 1 site in China. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Quanzhou First Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 762 open to participants now, 987 under way, 202 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.
Among the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 567th largest by planned enrollment of the 1,595 interventional ones that give a count, is one of 2 that started in 2027, is one of 652 in phase 2, reaches primary completion later than 972 of the 986 other live ones, and was the 1,881st registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →762 of the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:
Full-Life Technologies UK Limited · Sites in China, United States, Australia
Ages 18+
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18–70
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 60 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,882 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 361 · Phase 2 850 · Phase 3 404 · Phase 4 40
First in 1996; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 170 is above the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 100 across the 1,595 interventional studies, 200 across the 287 observational. Of the 455 that completed or were terminated, 130 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
805 of 1,882 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Quanzhou First Hospital as lead sponsor.
Quanzhou First Hospital has 1 study filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
225 of the studies in Carcinoma, Non-Small-Cell Lung with a site in China that are under way reach primary completion within a year, 33 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06448312Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2026-11 |
| NCT06704620Phase 3Tianjin Medical University Cancer Institute and HospitalStudy of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer | 2026-11 |
| NCT05429463Phase 3Second Affiliated Hospital, Zhejiang University, School of MedicineNeoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ) | 2026-11-30 |
| NCT06711900Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | 2026-12 |
| NCT06382129Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | 2026-12 |
Add all 225 to your calendar (.ics) → With an account.
Among the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the 12-month "treatment success" rate between a single SBRT dose of 30 Gy/1 and three SBRT doses totaling 54 Gy/3 in elderly or frail patients with early-stage NSCLC.
Study Design and Methods
Organs at Risk (OARs) and Dose Limits. The following must be assessed and reported: cardiac substructures (left anterior descending artery [LAD], left atrium, sinoatrial node), proximal bronchial tree, chest wall, brachial plexus, esophagus, and major vessels. The limits shall be set according to the existing standards for single-fraction SBRT implemented at our institution and included as an appendix to the treatment plan; for the B-arm, the three-fraction standard shall apply. Quality assurance (QA) shall be performed in accordance with ICRU 91 and our institution's SBRT QA protocol; prior to the initiation of this project, a single-fraction dosimetric audit must be completed, and it is recommended that end-to-end verification be performed on the first 10 enrolled cases.
Note: The specific values shall be subject to the appendix of the hospital's current SBRT dosimetry standards; this protocol does not pre-encode any limits that have not been approved by the hospital.
Inclusion Criteria:① Non-small cell lung cancer (NSCLC) confirmed by histology or cytology; or cases that have not yet undergone pathological confirmation but simultaneously meet all of the following criteria: (a) Chest CT demonstrates a peripheral solid nodule or mass with clear malignant imaging features (lobulation, spiculation, pleural retraction, post-contrast enhancement); (b) 18F-FDG PET/CT shows lesion uptake higher than that of the mediastinal blood pool, with no distant or mediastinal/hilar lymphadenopathy on whole-body imaging; (c) Previous imaging confirms lesion enlargement, or the doubling time is consistent with ; (d) After discussion by the lung cancer MDT, it is unanimously concluded that the likelihood of primary peripheral lung cancer is extremely high, and small cell lung cancer, pulmonary metastases, and other benign lesions have been excluded; (e) The patient is unsuitable for or unwilling to undergo due to poor cardiopulmonary functional reserve, multiple comorbidities, high puncture risk, or explicit refusal; (f) The clinical diagnostic process and conclusion are fully documented in the medical record and the study CRF. ② Peripheral tumors with a maximum diameter ≤3 cm and a stage of T1N0M0 (8th edition TNM, IA1-IA3); those with invasion of the visceral pleura or atelectasis classified as T2aN0M0 (IB) may also be eligible for inclusion. ③ At enrollment, whether the diagnosis was "histologically/ confirmed" is recorded (Yes/No) as a prespecified subgroup and sensitivity analysis factor (SAP), as predefined. ④ After enrollment, if pathology is obtained and confirms that the case is not NSCLC (e.g., small cell lung cancer), the patient will be withdrawn from the study treatment and receive standard treatment based on the actual pathology; such cases will be counted as protocol violations and included in the sensitivity analysis. ⑤ Age ≥75 years, or age \<75 years but meeting any of the following criteria: CCI ≥3, 2-3, positive G8 screening, or CFS ≥4 on the Clinical Frailty Scale; ⑥ assessed by thoracic surgery as unsuitable for surgery, or deemed operable but explicitly declined surgery by the patient (an MDT record must be retained); ⑦ ECOG 0-3; ⑧ expected survival ≥12 months; ⑨ signed Exclusion Criteria:① Central or supercentral tumors (single-dose fractionation is not applicable); ② Previous history of thoracic radiotherapy; ③ Active infection in the ipsilateral lung or mediastinum; ④ Severe interstitial lung disease (requiring oxygen therapy or FVC/DLCO \<35% of predicted value); ⑤ Patients requiring anticoagulation who cannot discontinue treatment due to a high risk of bleeding; ⑥ Presence of other malignant tumors within the preceding 5 years (excluding cured non-melanoma skin cancer and carcinoma in situ); ⑦ Patients who are unable to complete the 12-month follow-up or the PRO questionnaire; ⑧ Patients deemed unsuitable for enrollment by the investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single SBRT: 30 Gy / 1 session
Radiation: Radiotherapy dose fractionation regimen
3 sessions of SBRT, 18 Gy per session
Radiation: Radiotherapy dose fractionation regimen
single-session versus fractionated stereotactic radiotherapy
Overall Survival
Time frame: 12-month
Local Failure Free Survival
Time frame: 12-month
Serious Adverse Event Free Survival
Number of participants with grade ≥3 treatment-related adverse events as assessed by CTCAE v4.0
Time frame: 12-month
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2031, 59 months later.
Of 729 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 59 months is close to that.
Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →